ClinicalTrials.gg
CompletedNCT03799848Updated Mar 22, 2019

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

A Phase 1 interventional study of Vadadustat in Hepatic Impairment, sponsored by Akebia Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-22.

Sponsored by Akebia Therapeutics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2018, 8 years ago, and no results have been posted to the registry.
  • Registered 6 months after the study started (first participant enrolled Jun 2018, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a Phase I open-label study to evaluate the pharmacokinetic (PK) profile of a single oral dose of vadadustat in subjects with hepatic impairment(HI) compared to healthy matched control subjects with normal hepatic function.

Read the detailed description

This is an open label, parallel-group, single dose, Phase 1 study to evaluate the PK profile, safety, and tolerability of a single oral 450 mg dose of vadadustat in subjects with hepatic impairment relative to control subjects with normal hepatic function. The study will enroll up to 24 subjects in 3 groups of 8 subjects at 2 study sites. Blood samples for vadadustat PK and its metabolites will be collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, and 72 hours post-dose.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Hepatic impairment
  • Healthy subjects
  • Child-pugh
  • Vadadustat
03

In context

Lead sponsor

Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between ≥18 years and ≤70 years of age
  • Have a body weight ≥45 kg and (BMI) ≥18.5 kg/m2 to 40.0 kg/m2

Additional Group-Specific Inclusion Criteria:

  • Group 1 (Moderate Hepatic Impairment Subjects):

    • Presence of Moderate hepatic impairment ( Class B)
  • Group 2 (Normal Hepatic Function Subjects):

    • Normal hepatic function
  • Group 3 (Mild Hepatic Impairment Subjects):

    • Presence of mild hepatic impairment ( Child-Pugh Class A)

Exclusion criteria

Exclusion Criteria (all groups):

  • Renal impairment ≥ Stage 3 (estimated [eGFR] \<60 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) study equation)
  • Any history of active within 2 years prior to or during screening, except for treated basal cell carcinoma of skin, curatively resected squamous cell carcinoma of skin, or cervical carcinoma in situ; any history of tuberculosis and/or prophylaxis for tuberculosis
  • Positive test for (HIV) antibody at Screening.
  • Hepatic or other organ or cell transplant
  • Subjects with alcoholic cirrhosis must be sober for a minimum of 6 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Vadadustat

    Group 1: Subjects with moderately impaired hepatic function (Child-Pugh Class B) Group 2: Normal healthy volunteers Group 3: Subjects with mildly impaired hepatic function (Child-Pugh Class A)

    Drug: Vadadustat

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from dosing to last measurable concentration (AUClast)

    Time frame: Day 1, Day 4

  2. Area under the concentration-time curve from dosing to infinity (AUCinf)

    Time frame: Day 1, Day 4

  3. Observed maximum concentration (Cmax).

    Time frame: Day 1, Day 4

Secondary outcomes

  1. Time to reach Cmax of vadadustat

    Time frame: Day 1, Day 4

  2. Apparent total body clearance (CL/F) of vadadustat

    Time frame: Day 1, Day 4

  3. Apparent volume of distribution (Vd/F) of vadadustat

    Time frame: Day 1, Day 4

  4. Terminal half-life (t1/2) of vadadustat

    Time frame: Day 1, Day 4

  5. Time to reach Tmax of vadadustat

    Time frame: Day 1, Day 4

  6. Assessment of Treatment-Emergent Adverse Events (TEAEs) as reported by study subjects

    Time frame: Up to 9 Weeks

  7. Cmax related to free drug (Cmax, free) of Vadadustat Unbound

    Time frame: Day 1, Day 4

  8. AUClast related to free drug (AUClast, free) of Vadadustat Unbound

    Time frame: Day 1, Day 4

  9. AUCinf related to free drug (AUCinf, free) of Vadadustat Unbound

    Time frame: Day 1, Day 4

  10. CL/F related to free drug (CL/Ffree) of Vadadustat Unbound

    Time frame: Day 1, Day 4

  11. Terminal half-life (t1/2) of Vadadustat Unbound

    Time frame: Day 1, Day 4

  12. The area under the concentration-time curve from dosing to last measurable concentration (AUClast) of Vadadustat metabolites

    Time frame: Day 1, Day 4

  13. The area under the concentration-time curve from dosing to infinity (AUCinf) of Vadadustat metabolite

    Time frame: Day 1, Day 4

  14. Time to reach Cmax of vadadustat metabolites

    Time frame: Day 1, Day 4

  15. Terminal half-life (t1/2) of Vadadustat metabolites

    Time frame: Day 1, Day 4

  16. Renal clearance (CLr) of Vadadustat/metabolite(s) Urine

    Time frame: Day 1, Day 4

  17. Cumulative amount of drug excreted (Ae) of Vadadustat/metabolite(s) Urine

    Time frame: Day 1, Day 4

  18. Cumulative fraction of drug excreted (Fe) of Vadadustat/metabolite(s) Urine

    Time frame: Day 1, Day 4

07

Study locations

2 sites
  • Prism Clinical Research
    Saint Paul, Minnesota 55114, United States
  • American Research Corporation at the University of Texas Liver Institute
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Oct 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2018
First posted
Jan 10, 2019
StartActual
Jun 12, 2018
Primary completionActual
Oct 18, 2018
CompletionActual
Oct 18, 2018
Last update
Mar 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03799848
Responsible party
Sponsor
First posted
Jan 10, 2019
Start date
Jun 12, 2018
Primary completion
Oct 18, 2018
Completion
Oct 18, 2018
Last update
Mar 22, 2019

Study contacts

Akebia Therapeutics
study director · Akebia Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion